Journal article

Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic

Louise Rath, Minh Viet Bui, Julian Ellis, John Carey, Josephine Baker, Lisa Taylor, Hasini Fernando, Nicola Taylor, Poppy Savage, Janene Richards, Michael Zhong, Tomas Kalincik, Olga Skibina, Robb Wesselingh, Ai-Lan Nguyen, Mastura Monif, Helmut Butzkueven, Anneke van der Walt

MULTIPLE SCLEROSIS AND RELATED DISORDERS | ELSEVIER SCI LTD | Published : 2021

Abstract

BACKGROUND: The COVID-19 pandemic challenges multiple sclerosis services to be innovative in delivering infusible therapies. To reduce time in clinical settings, and potential staff or space losses, we implemented rapid infusion protocols for selected patients. OBJECTIVE: To analyse the rate of infusion related reactions and patient experience of rapid infusions of natalizumab and ocrelizumab. To document time reduction patients spent in clinical settings during the COVID-19 pandemic. METHODS: Patients with prior exposure to at least three natalizumab or two 300mg ocrelizumab infusions were approved for rapid protocols. A retrospective audit and survey were completed. RESULTS: We analysed 26..

View full abstract